Home/Xenon Pharmaceuticals/Robin Sherrington
RS

Robin Sherrington

Executive Vice President, Strategy and Innovation

Xenon Pharmaceuticals

Therapeutic Areas

Xenon Pharmaceuticals Pipeline

DrugIndicationPhase
Azetukalner (XEN1101)Focal Onset SeizuresPhase 3
XEN1701PainPhase 1
XEN1120Undisclosed (Kv7 target)Phase 1